Op/Ed: Why Rare Disease Brands Are Losing Patients at Critical Moments

Key Takeaways

• Journey maps focus on prescribing, ignore post‑diagnosis logistics
• Rare‑disease access stalls at referral, prior authorization, hub enrollment
• Specialists lack muscle memory for infrequent access processes
• Align messages to handoff moments improves HCP support, patient start
• Shared framework between commercial and market‑access teams reduces abandonment

Pulse Analysis

In specialty pharma, journey maps have traditionally been built around the commercial funnel—awareness, consideration, prescribing intent. That framework served well when the primary obstacle was convincing physicians to choose one molecule over another. However, for rare‑disease therapies the decisive moment often occurs after the prescription is written. The logistics of referral handoffs, benefits verification, prior‑authorization submissions, and enrollment in manufacturer‑run hubs are rarely captured in these maps, leaving a blind spot that can halt a patient’s path to treatment.

Because rare‑disease specialists see only a handful of cases per year, they lack the muscle memory that primary‑care doctors develop for routine prior‑authorization cycles. Each new patient therefore triggers a series of unfamiliar steps, and without real‑time guidance the process stalls. The consequence is not a delayed refill but a complete loss of therapy initiation, eroding both patient outcomes and the brand’s market share. Data from Conexus Solutions shows that hub‑enrollment failures represent the highest abandonment point, underscoring how operational friction directly translates into revenue leakage.

Pharma can close the gap by redesigning journey maps to mirror the access pathway instead of the commercial funnel. At each handoff—diagnosis, prior‑authorization initiation, hub enrollment—messaging should deliver precise documentation guides, criteria language, and direct contacts for reimbursement teams. Aligning commercial, market‑access, and hub operations around a shared framework creates a seamless experience for physicians and their staff, reducing drop‑off rates and accelerating time‑to‑therapy. As more rare‑disease brands adopt this operational‑first mindset, the industry can expect higher patient adherence, stronger payer relationships, and sustainable revenue growth. Ultimately, patient‑centric mapping becomes a competitive differentiator in an increasingly value‑based market.